
ESLA
Healthcare · Biotechnology · $22.4M market cap
$0.5037-0.02 (-2.9%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · 30-day revisions 1 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 13, 2026 | After the close | -0.09 | -0.05 | +44.4% |
| May 18, 2026 | Before the open | -0.19 | -0.05 | +73.7% |
| Mar 18, 2026 | Before the open | -0.07 | -0.01 | +85.7% |
| Nov 12, 2025 | After the close | -0.07 | -0.13 | -85.7% |
| Aug 12, 2025 | Before the open | -0.12 | -0.15 | -25.0% |
| May 14, 2025 | After the close | -0.11 | -0.06 | +45.5% |
| Mar 25, 2025 | After the close | -0.12 | -0.03 | +75.0% |
| Nov 14, 2024 | Time not confirmed | -0.12 | -0.09 | +25.0% |
| Mar 14, 2023 | Time not confirmed | — | -0.11 | — |
| Nov 14, 2022 | Time not confirmed | — | -0.06 | — |
| Aug 8, 2022 | Time not confirmed | — | -0.06 | — |
| May 16, 2022 | Time not confirmed | — | -0.02 | — |
| Mar 29, 2022 | Time not confirmed | — | -0.12 |
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201,…
| — |
| Nov 10, 2021 | Time not confirmed | — | -0.02 | — |
| Jul 19, 2021 | Time not confirmed | — | 0.00 | — |